<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology and pathophysiology of benign prostatic hyperplasia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology and pathophysiology of benign prostatic hyperplasia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology and pathophysiology of benign prostatic hyperplasia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin T McVary, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael P O'Leary, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karen Law, MD, FACP
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 22, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION/DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benign prostatic hyperplasia (BPH) is a common problem among older men that negatively impacts quality of life and results in considerable medical intervention and expense [
         <a href="#rid1">
          1
         </a>
         ]. BPH is a histologic diagnosis defined as an increase in the total number of stromal and glandular epithelial cells within the transition zone of the prostate gland. This hyperplasia causes formation of large, discrete prostatic nodules.
        </p>
        <p>
         The diagnosis and management of BPH are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6889.html" rel="external">
          "Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6891.html" rel="external">
          "Medical treatment of benign prostatic hyperplasia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8093.html" rel="external">
          "Surgical treatment of benign prostatic hyperplasia (BPH)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H228039013">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benign prostatic hyperplasia (BPH) is often confused with benign prostatic hypertrophy, which is an archaic term for BPH describing an increase in cell size rather than cell number. BPH results in benign prostatic enlargement (BPE) in some, but not all men. This enlargement can, in turn, lead to benign prostatic obstruction (BPO) and bladder outlet obstruction (BOO). While BPH alone does not require treatment, BPE and BPO are often associated with lower urinary tract symptoms (LUTS), which may require treatment.
        </p>
        <p>
         LUTS is a clinical term describing symptoms related to the bladder and the urethra. It can be caused by a variety of conditions but is often attributed to BPH. LUTS can be subdivided into symptoms of urinary storage (eg, urgency, frequency, nocturia, etc), symptoms of urinary voiding (eg, straining to void, urinary intermittency, dysuria, hesitancy, etc) and post-voiding symptoms (eg, sensation of incomplete bladder emptying, post-void urinary dribbling, etc).
        </p>
        <p>
         In the discussion below, LUTS/BPH will be used to indicate LUTS attributed to BPH, in accordance with the American Urological Association BPH clinical
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.auanet.org%2Fguidelines-and-quality%2Fguidelines%2Fbenign-prostatic-hyperplasia-%28bph%29-guideline&amp;token=04usxcqhVrf3qk6zmtBNw2IQSOxuXCVn6umAr4HwqNVl5h%2Fiq5BhAWIpg5yxwwnKE%2FzUochFYAxz39ZGD8tyd33uxfcJwRrACOPqZFXDt7yCQkwps0IBlf0sOFPsTW9a&amp;TOPIC_ID=6890" target="_blank">
          guidelines
         </a>
         . LUTS is described in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6879.html" rel="external">
          "Lower urinary tract symptoms in males"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H2795321574">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of benign prostatic hyperplasia (BPH) increases with age.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Based on medical records, it has been estimated that nearly 70 percent of United States men between the ages of 60 and 69 years, and nearly 80 percent of men ≥70 years, have some degree of BPH [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The prevalence of histologically diagnosed BPH increases from 8 percent in men aged 31 to 40, to 40 to 50 percent in men aged 51 to 60, to over 80 percent in men older than age 80 (
         <a class="graphic graphic_figure graphicRef55614" href="/z/d/graphic/55614.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mirroring changes in BPH, the prevalence and severity of lower urinary tract symptoms (LUTS) in men appears to be age-related. (See
         <a class="medical medical_review" href="/z/d/html/6879.html" rel="external">
          "Lower urinary tract symptoms in males", section on 'Prevalence and risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3123940457">
         <span class="h2">
          Risk factors
         </span>
        </p>
        <p class="headingAnchor" id="H890388881">
         <span class="h3">
          Unmodifiable risk factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Race
         </strong>
         – Race has some influence on the risk for BPH severe enough to require surgery. While the age-adjusted relative risk (RR) of BPH necessitating surgery is similar in Black and White men, Black men younger than 65 years old need treatment more often than White men [
         <a href="#rid3">
          3
         </a>
         ]. In a community sample of 2480 men in the United States, moderate to severe LUTS was more common in Black men than White men (41 versus 34 percent) [
         <a href="#rid4">
          4
         </a>
         ], and Black men had greater total and transitional zone prostate volume [
         <a href="#rid5">
          5,6
         </a>
         ]. However, this association may be confounded by socioeconomic factors such as income and insurance [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a study of 34,624 men, Asian men had a lower risk of clinician-diagnosed BPH (RR 0.7, CI 0.2-0.5) compared with Black and White men, who had similar risk [
         <a href="#rid8">
          8
         </a>
         ]. Additionally, in the American Male Health Professional Study, Asian American men were less likely (RR 0.4, 95% CI 0.2-0.8) to undergo surgery for BPH compared with White men [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic susceptibility
         </strong>
         – A role for genetic factors is suggested by studies of familial tendencies towards BPH and by genetic studies. Familial BPH is characterized by larger prostate size and diagnosis at an earlier age than sporadic BPH [
         <a href="#rid10">
          10
         </a>
         ]. Twin studies suggest that genetic factors are a more important determinant of LUTS than age, transition zone volume, or total prostate volume [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Various studies have shown familial tendencies. In one study, men with three or more affected family members had large prostate glands, above-normal serum androgen concentrations, and a normal response to 5-alpha-reductase inhibition [
         <a href="#rid10">
          10
         </a>
         ]. In a survey of men in Olmsted County, Minnesota, 21 percent of 2119 men between 40 and 70 years of age had a family history of an enlarged prostate [
         <a href="#rid12">
          12
         </a>
         ]. The odds ratio [OR] of a man with a positive family history of BPH having moderate to severe LUTS was 1.3 (95% CI, 1.1-1.7).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The possible role of genetic factors was evaluated in several studies. A genome-wide association study (GWAS) of men from three independent populations indicated that genetic variants of
         <em>
          GATA3
         </em>
         may play a role in the inherited susceptibility and etiology of BPH/LUTS [
         <a href="#rid13">
          13
         </a>
         ] A 2014 systematic review and meta-analysis of genes that may cause urinary symptoms in men only found a variant of the vitamin D receptor that was consistently protective across different populations [
         <a href="#rid14">
          14
         </a>
         ]. In a case-control study of men under 64 years of age who had undergone prostatectomy for BPH and in whom more than 37 grams of tissue were resected, the first-degree relatives of these men had a fourfold increased risk of developing BPH that required surgical therapy as compared with the relatives of normal men [
         <a href="#rid15">
          15
         </a>
         ]. Segregation analysis suggested an autosomal dominant mode of disease transmission (with an estimated penetrance of 0.89) and an allele frequency of 3.4 percent in the population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hormone levels
         </strong>
         – Serum testosterone or DHT concentrations do not appear to be higher in men who develop prostate hyperplasia; The Physicians' Health Study found similar serum testosterone concentrations at the initial examination in 320 men who had BPH treated surgically up to nine years later and 320 men who did not develop prostatic disease [
         <a href="#rid16">
          16
         </a>
         ]. In fact, higher serum levels of testosterone and estradiol were associated with decreased risk of future development of symptomatic BPH in the Prostate Cancer Prevention Trial [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The role of estrogen is unclear. There is an increase in the ratio of estrogen to androgen in the serum in older men which suggests a possible role for estrogen in the maintenance, but not necessarily the causation, of BPH. The age-related increase in the serum estrogen-androgen ratio is associated with an increase in the estrogen-androgen ratio in prostatic tissue, especially in the stroma [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Family history of cancer
         </strong>
         – The risk of BPH is increased in men with a family history of bladder cancer but not with a family history of prostate cancer [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2276976563">
         <span class="h3">
          Modifiable risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some modifiable factors may play a role in the development of LUTS/BPH [
         <a href="#rid20">
          20-23
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metabolic factors: Obesity and metabolic syndrome
         </strong>
         – The development of LUTS/BPH appears to be related, in part, to increased autonomic tone and to the metabolic syndrome (obesity, glucose intolerance, dyslipidemia, and hypertension) [
         <a href="#rid20">
          20-22,24
         </a>
         ]. This relationship may be due to increased aromatization of circulating testosterone in adipose tissue, which alters the testosterone to estrogen ratio, or to hyperinsulinemia [
         <a href="#rid21">
          21
         </a>
         ]. Two meta-analyses found that men with the metabolic syndrome had higher prostate growth rates and larger prostate volume than those without the metabolic syndrome [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Beverage consumption
         </strong>
         – Greater coffee or total caffeine intake increases the odds of LUTS/BPH progression. Citrus juice intake was associated with 50 percent lower odds of LUTS/BPH progression [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical activity
         </strong>
         – Lower levels of physical activity are associated with greater development of LUTS [
         <a href="#rid28">
          28
         </a>
         ]. Frailty is also associated with greater risk of BPH progression and serious adverse events requiring hospitalization [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alcohol consumption
         </strong>
         – Moderate alcohol consumption is not associated with LUTS/BPH [
         <a href="#rid28">
          28
         </a>
         ]. However, excessive consumption (three or more drinks per day) may lower the risk of BPH due to depression of androgen levels [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dietary factors
         </strong>
         – LUTS/BPH may be related to micronutrients involved in prevention of oxidative damage or cell growth and differentiation. Dietary lycopene,
         <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">
          beta-carotene
         </a>
         , total carotenoids, and vitamin A are inversely associated with LUTS, although high-dose supplemental and total
         <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">
          vitamin C
         </a>
         are positively associated with LUTS [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2742351267">
         <span class="h3">
          Conditions exacerbating LUTS/BPH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many medical conditions can influence the severity of LUTS.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular risk factors
         </strong>
         – Alpha-adrenergic fibers and receptors play important roles in both hypertension and symptomatic BPH. Autonomic hyperactivity is believed to be involved in the development of LUTS [
         <a href="#rid32">
          32
         </a>
         ], and heart disease and hypertension are associated with greater LUTS severity [
         <a href="#rid33">
          33
         </a>
         ]. In patients with heart failure, changes in cardiac ventricular pressure cause release of B-type natriuretic peptide (BNP). This, in addition to peripheral edema, can increase urine production resulting in worsening of urinary symptoms, especially at night [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic factors
         </strong>
         – Neurologic conditions that influence detrusor function and stability are important in patients with LUTS/BPH because they may add to the complexity of diagnosis and affect therapeutic decision-making. Patients with Parkinson disease frequently develop voiding dysfunction, most commonly detrusor overactivity with impaired detrusor contractility. Patients with multiple sclerosis (MS) will likely develop urinary symptoms at some point in the disease process. Cerebral vascular accidents may result in a transient spinal shock-like period of detrusor areflexia, placing the patient at risk for urinary retention, followed by most commonly neurogenic detrusor overactivity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diabetes mellitus
         </strong>
         – Diabetes can worsen LUTS due to decreased bladder sensation, decreased detrusor contractility, and incomplete bladder emptying. Additionally, increased filtration of glucose in the urine leads to an osmotic diuresis and polyuria, thereby potentially worsening LUTS due to increased urine production.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1554269319">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathophysiology of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) is likely multifactorial, with the prostate playing a significant, but likely over-emphasized role in its etiology [
         <a href="#rid35">
          35
         </a>
         ]. Nevertheless, the prostatic contribution to LUTS can be thought of as having a static component, referring to enlargement of the prostatic gland leading to benign prostatic obstruction (BPO), and a dynamic component consisting of increased smooth muscle tone and resistance. Benign prostatic enlargement (BPE) with BPO can have secondary effects on detrusor activity, leading to detrusor instability or overactive bladder (OAB). This effect, in combination with age-related changes to detrusor contraction and compliance, compounds BPH-associated LUTS.
        </p>
        <p>
         Several processes are likely involved including increased production of new epithelial glands, re-establishment of prostatic cells’ inductive potential, and cell immortalization due to loss of programmed cell death.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Androgens play a key role in the proliferation of prostatic cells and inhibition of cell death [
         <a href="#rid36">
          36
         </a>
         ]. For example, prostatic hyperplasia does not occur in pre-pubertal males when testosterone and dihydrotestosterone (DHT) levels are low but does occur during the post-pubertal period when androgen levels are elevated. In addition, individuals who have had castration prior to puberty or who exhibit impairment in androgen production or androgen receptors do not develop BPH. Lastly, prostatic tissue undergoes involution in androgen withdrawal [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic and localized inflammation are associated with LUTS/BPH [
         <a href="#rid38">
          38-40
         </a>
         ]. Although causal factors are unknown, possible etiologies include obesity-related inflammation, autoimmune processes, and chronic infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Serum level C-reactive protein levels correlate with LUTS severity [
         <a href="#rid41">
          41
         </a>
         ]. In addition, inflammation, as assessed by cytological and immunohistochemical parameters is associated with higher International Prostate Symptom Scores (IPSS) and greater prostate volume [
         <a href="#rid42">
          42
         </a>
         ]. This association may explain the association between obesity and LUTS/BPH, as obesity is associated with increased inflammatory cytokines. Dietary fats have been implicated, and lipopolysaccharides can induce prostatic inflammation in experimental animals. It has been hypothesized that macrophages secrete cytokines that stimulate stromal and epithelial hyperplasia. Investigators have found increased concentrations of hypoxia-inducible factor (HIF)-1 alpha, which can be secreted by epithelial cells and is known to be induced by proinflammatory cytokines and to be involved in testosterone-mediated hyperplasia [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If inflammation is a causal mechanism for LUTS/BPH, it also could provide an explanation for improvement with nonsteroidal antiinflammatory drugs (NSAIDs) [
         <a href="#rid44">
          44
         </a>
         ]. There is also some evidence that phosphodiesterase-5 inhibitors decrease fibroblast to myofibroblast transdifferentiation, which could be a mechanism by which they decrease symptoms [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Inflammation could be caused by an autoimmune process or in response to chronic infection. Investigators have failed to associate BPH with any of 17 single-nucleotide polymorphisms in genes involved in obesity [
         <a href="#rid46">
          46
         </a>
         ]. The lymphotoxin-beta-receptor (LT-beta-R) gene has been reported to be involved in autoimmune disease and inflammatory disorders. Korean investigators found nucleotide polymorphisms located in the promoter and coding regions of LT-beta-R in BPH tissue, and an allele was significantly associated with BPH [
         <a href="#rid47">
          47
         </a>
         ]. Heat shock protein (HSP) 27 is also known as a mediator in immune responses. Expression of HSP27 is reported to increase with increasing inflammation in BPH tissue [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Investigators have sought to identify chronic infections that might cause prostatitis. One possibility is
         <em>
          Escherichia coli
         </em>
         . It is postulated that phospholipase D, which is attached to the outer membrane of
         <em>
          E. coli
         </em>
         , stimulates the production of lysophosphatidic acid (LPA), and LPA stimulates other factors that cause inflammation [
         <a href="#rid49">
          49
         </a>
         ]. Another approach to understanding inflammation in BPH tissue has been to measure heme oxygenase (HO). HO has been found to be inversely related to inflammation in the prostate [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4242258943">
         <span class="h1">
          HISTOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benign prostatic hyperplasia (BPH) develops primarily in the periurethral or transitional zone of the prostate. The hyperplastic nodules are comprised primarily of stromal components and, to a lesser degree, epithelial cells. In one immunohistochemical study, stroma comprised 62 percent of the volume, epithelium 15 percent, and glandular lumens 23 percent; the stromal to epithelial ratio was 4.6 [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H30182019">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15355.html" rel="external">
          "Patient education: Benign prostatic hyperplasia (enlarged prostate) (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4849.html" rel="external">
          "Patient education: Benign prostatic hyperplasia (BPH) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The prevalence of histologically diagnosed benign prostatic hyperplasia (BPH) increases with age. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The pathophysiology of BPH remains incompletely understood but is likely multifactorial. Increased risk of BPH may be related to inflammation and metabolic factors. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         BPH develops primarily in the periurethral or transitional zone of the prostate. (See
         <a class="local">
          'Histology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although testosterone, dihydrotestosterone (DHT), and estrogen may be involved in the development of BPH, these hormones alone are not sufficient to cause BPH. (See
         <a class="local">
          'Unmodifiable risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The development of lower urinary tract symptoms (LUTS)/BPH appears to be related, in part, to increased autonomic tone and to the metabolic syndrome (obesity, glucose intolerance, dyslipidemia, and hypertension). (See
         <a class="local">
          'Modifiable risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H102241469">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Glenn Cunningham, MD, and Dov Kadmon, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidney S, Quesenberry CP Jr, Sadler MC, et al. Incidence of surgically treated benign prostatic hypertrophy and of prostate cancer among blacks and whites in a prepaid health care plan. Am J Epidemiol 1991; 134:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarma AV, Wei JT, Jacobson DJ, et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. Urology 2003; 61:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler JE Jr, Bigler SA, Kilambi NK, Land SA. Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies. Urology 1999; 53:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan SA, Reis RB, Staimen VB, Te AE. Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic counterparts? Br J Urol 1998; 82:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowke JH, Munro H, Signorello LB, et al. Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med 2011; 26:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang D, Andriole GL, Van De Vooren RC, et al. Risk behaviours and benign prostatic hyperplasia. BJU Int 2004; 93:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Platz EA, Kawachi I, Rimm EB, et al. Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study. J Urol 2000; 163:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanda MG, Doehring CB, Binkowitz B, et al. Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol 1997; 157:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meikle AW, Bansal A, Murray DK, et al. Heritability of the symptoms of benign prostatic hyperplasia and the roles of age and zonal prostate volumes in twins. Urology 1999; 53:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts RO, Rhodes T, Panser LA, et al. Association between family history of benign prostatic hyperplasia and urinary symptoms: results of a population-based study. Am J Epidemiol 1995; 142:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Na R, Helfand BT, Chen H, et al. A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Prostate 2017; 77:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartwright R, Mangera A, Tikkinen KA, et al. Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men. Eur Urol 2014; 66:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanda MG, Beaty TH, Stutzman RE, et al. Genetic susceptibility of benign prostatic hyperplasia. J Urol 1994; 152:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gann PH, Hennekens CH, Longcope C, et al. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995; 26:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kristal AR, Schenk JM, Song Y, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2008; 168:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krieg M, Nass R, Tunn S. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993; 77:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Negri E, Pelucchi C, Talamini R, et al. Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia. Int J Cancer 2005; 114:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupelian V, McVary KT, Kaplan SA, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 2009; 182:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McVary KT, Razzaq A, Lee C, et al. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994; 51:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 2013; 189:S102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang JY, Fu YY, Kang DY. The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2016; 95:e3243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zou C, Gong D, Fang N, Fan Y. Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol 2016; 34:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maserejian NN, Wager CG, Giovannucci EL, et al. Intake of caffeinated, carbonated, or citrus beverage types and development of lower urinary tract symptoms in men and women. Am J Epidemiol 2013; 177:1399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maserejian NN, Kupelian V, Miyasato G, et al. Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J Urol 2012; 188:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer SR, Walter LC, Ensrud KE, et al. Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. JAMA Netw Open 2021; 4:e2134427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crispo A, Talamini R, Gallus S, et al. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. Urology 2004; 64:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maserejian NN, Giovannucci EL, McVary KT, McKinlay JB. Dietary, but not supplemental, intakes of carotenoids and vitamin C are associated with decreased odds of lower urinary tract symptoms in men. J Nutr 2011; 141:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell S, McVary KT. Lower urinary tract symptoms and erectile dysfunction: epidemiology and treatment in the aging man. Curr Urol Rep 2005; 6:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coyne KS, Kaplan SA, Chapple CR, et al. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int 2009; 103 Suppl 3:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoshiyama F, Hirayama A, Tanaka M, et al. The impact of obstructive sleep apnea syndrome on nocturnal urine production in older men with nocturia. Urology 2014; 84:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de la Rosette JJ, Witjes WP, Schäfer W, et al. Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the ICS-"BPH" study. Neurourol Urodyn 1998; 17:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984; 5:545.
          </a>
         </li>
         <li class="breakAll">
          Grayhack JT, McVary KT, Kozlowski JM. Benign prostatic hyperplasia. In: Adult and Pediatric Urology, 4th, Gillenwater JJ, Grayhack JT, Howards SS, Mitchell ME (Eds), Lippincott Williams &amp; Wilkins, Philadelpha 2002. Vol 2, p.1401.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd GL, Ricke WA, McVary KT. Inflammation, Voiding and Benign Prostatic Hyperplasia Progression. J Urol 2019; 201:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasturi S, Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006; 7:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupelian V, McVary KT, Kaplan SA, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey. J Urol 2013; 189:S107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupelian V, McVary KT, Barry MJ, et al. Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey. Urology 2009; 73:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robert G, Descazeaud A, Nicolaïew N, et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009; 69:1774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HJ, Park JW, Cho YS, et al. Pathogenic role of HIF-1α in prostate hyperplasia in the presence of chronic inflammation. Biochim Biophys Acta 2013; 1832:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int 2013; 111:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zenzmaier C, Kern J, Sampson N, et al. Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation. Endocrinology 2012; 153:5546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez DS, Peskoe SB, Tsilidis KK, et al. Association of variants in genes related to the immune response and obesity with BPH in CLUE II. Prostate Cancer Prostatic Dis 2014; 17:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SH, Kim SK, Yoo KH, et al. Association of LTβR gene polymorphisms with prostate volume in benign prostatic hyperplasia in the Korean population. Genet Mol Res 2015; 14:18607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang Y, Wang X, Guo Y, et al. Expression of Heat Shock Protein 27 in Benign Prostatic Hyperplasia with Chronic Inflammation. Med Sci Monit 2015; 21:2976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roper WG. The prevention of benign prostatic hyperplasia (bph). Med Hypotheses 2017; 100:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russo GI, Vanella L, Castelli T, et al. Heme oxygenase levels and metaflammation in benign prostatic hyperplasia patients. World J Urol 2016; 34:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992; 147:1293.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6890 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15758764" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Urologic diseases in America project: benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6206240" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The development of human benign prostatic hyperplasia with age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1719806" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Incidence of surgically treated benign prostatic hypertrophy and of prostate cancer among blacks and whites in a prepaid health care plan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12809866" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10367848" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9883215" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic counterparts?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21720905" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15180615" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Risk behaviours and benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10647663" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9072590" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical and biological characteristics of familial benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10197844" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Heritability of the symptoms of benign prostatic hyperplasia and the roles of age and zonal prostate volumes in twins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7572978" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Association between family history of benign prostatic hyperplasia and urinary symptoms: results of a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28656603" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24491308" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7515446" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Genetic susceptibility of benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7531326" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18945688" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7688377" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15578689" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19539955" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11223674" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16145413" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7918880" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Growth of the rat prostate gland is facilitated by the autonomic nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23234610" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27175628" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26119349" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23722012" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Intake of caffeinated, carbonated, or citrus beverage types and development of lower urinary tract symptoms in men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22704109" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34817584" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15491708" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Alcohol and the risk of prostate cancer and benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21178086" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Dietary, but not supplemental, intakes of carotenoids and vitamin C are associated with decreased odds of lower urinary tract symptoms in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16238919" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Lower urinary tract symptoms and erectile dysfunction: epidemiology and treatment in the aging man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19302499" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25096335" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The impact of obstructive sleep apnea syndrome on nocturnal urine production in older men with nocturia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9514142" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the ICS-"BPH" study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6483690" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Antagonistic effect of androgen on prostatic cell death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6483690" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Antagonistic effect of androgen on prostatic cell death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30694937" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Inflammation, Voiding and Benign Prostatic Hyperplasia Progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16930500" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23234611" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19394490" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19670242" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22986049" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pathogenic role of HIF-1αin prostate hyperplasia in the presence of chronic inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23356748" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22948216" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25224558" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Association of variants in genes related to the immune response and obesity with BPH in CLUE II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26782510" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Association of LTβR gene polymorphisms with prostate volume in benign prostatic hyperplasia in the Korean population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26434601" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Expression of Heat Shock Protein 27 in Benign Prostatic Hyperplasia with Chronic Inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28236846" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The prevention of benign prostatic hyperplasia (bph).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26621207" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Heme oxygenase levels and metaflammation in benign prostatic hyperplasia patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1373778" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
